

Revising Oral Pharmacokinetics, Bioavailability and Bioequivalence Based on the Finite Absorption Time Concept

Panos Macheras • Athanasios A. Tsekouras

Revising Oral
Pharmacokinetics,
Bioavailability
and Bioequivalence Based
on the Finite Absorption Time
Concept



Springer

Panos Macheras
Faculty of Pharmacy
National and Kapodistrian
University of Athens & ATHENA
Research Center
Athens, Greece

Athanasios A. Tsekouras
Department of Chemistry
National and Kapodistrian
University of Athens & ATHENA
Research Center
Athens, Greece

ISBN 978-3-031-20024-3 ISBN 978-3-031-20025-0 (eBook)
<https://doi.org/10.1007/978-3-031-20025-0>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*Dedicated to our children and grandchildren
Evangelos, Spiros, Andreas, Giorgos,
Artemis, Thalís, Stefanos, Panos and Amelia*

Foreword

It is rare and refreshing to see a well-researched treatise that challenges a long-held scientific approach that obviously deserves scrutiny. Real-world oral pharmacokinetic curves not uncommonly show unexplained up-and-down patterns in the ascending or absorption part of overall bell-shaped concentration-time trajectories, followed by a sharp decline in concentration after the observed maximum concentration (C_{\max}). Such datasets are not well modeled using conventional compartmental models. The long overlooked Finite Absorption Time (FAT) concept, as manifested in the Physiologically Based Finite Time Pharmacokinetic (PBFTP) models described in this book, offers a sound theoretical foundation to address such shortcomings of conventional oral pharmacokinetic models. It may come as a delight to pharmacometricians to be able to adequately fit oral pharmacokinetic curves with strange double peaks or zigzag patterns in the absorption portion of the curve, often attributed to randomness of data or experimental aberrations using conventional approaches.

As discussed in Chap. 7, the FAT/PBFTP approach may contribute a supportive basis for regulatory recommendations to using partial AUC values (pAUC) for bioequivalence (BE) assessments. pAUC values can be usefully employed when a formulation change leads to a modified exposure response relationship without affecting C_{\max} and AUC. For example, the FDA recommended the use of partial AUC pAUC determinations for demonstrating BE of generic zolpidem extended-release tablets and methylphenidate hydrochloride ER capsules in 2011. As of June 2022, the FDA has issued 44 product-specific guidances recommending the use of pAUC to determine BE for drugs submitted via an ANDA. Consideration for using pAUCs in BE metrics and the selection of time intervals to truncate the AUC are both drug- and formulation-specific. PBFTP modeling can guide understanding of how a formulation interacts with segmental gastrointestinal physiology as reflected in the observed PK curves.

Critical evaluation is required of any new scientific approach that is proposed to improve on a long-practiced basis for characterizing PK and BE, which are key to evaluation of new or generic drugs. The authors are to be commended for challenging oral pharmacokinetic traditional models of drug absorption that perform poorly

in some circumstances. Via this well-written book, the scientific community can learn of the FAT concept and evaluate its value proposition seriously.

Disclaimer: This article reflects the views of the authors and should not be construed to represent FDA's views or policies.

NDA Partners, a ProPharma Group
Company, Washington, DC, USA

Carl Peck

Department of Bioengineering and
Therapeutic Sciences, University of
California at San Francisco, CA, USA

Division of Quantitative Methods and
Modeling, Office of Research and
Standards, US Food and Drug
Administration, Silver Spring, MD,
USA

Liang Zhao

Preface

According to the Editor of Journal of Pharmacokinetics and Pharmacodynamics Dr Peter Bonate [1] “in a few short years, quantitative systems pharmacology (QSP) has become a major tool available to pharmacometricians to improve decision making in drug development, so much so that today pharmacometrics can be broadly classified into three groups: population-based methods, physiologically-based pharmacokinetics (PBPK), and Quantitative Systems Pharmacology (QSP). Recently, we are starting to see the emergence of a fourth field: machine learning.” This is so since science progresses. It evolves. New knowledge is created. Pharmacometrics is no exception [1].

In the midst of these dramatic changes, we realized in 2019 that a wrong assumption that breaks oral pharmacokinetics was used and extensively applied since 1953 [2]. In fact, the infinite time of oral drug absorption was conceived from the first day of the birth of pharmacokinetics when F. H. Dost introduced the term pharmacokinetics [2]. He adopted the function developed by H. Bateman [3] back in 1910 for the decay of the radioactive isotopes to describe oral drug absorption as a first-order process. We unveiled this false hypothesis relying on common wisdom, i.e., drugs are absorbed in finite time. This false assumption had dramatic effects on the evolution of oral pharmacokinetics, but most importantly on the bioavailability and bioequivalence concepts and metrics. Accordingly, the title of this book could be “*Unveiling the wrong assumption that breaks oral pharmacokinetics: Drugs are absorbed in finite time.*” Instead, we utilize a different title which places emphasis on the “*revision*” of the three major disciplines of biopharmaceutics-pharmacokinetics, namely, oral pharmacokinetics, bioavailability, and bioequivalence under the prism of Finite Absorption Time (FAT).

In oral pharmacokinetics, the absorption rate constant became the sole parameter for expressing quantitatively the rate of drug absorption in classical and population pharmacokinetic studies. However, it was found to be the most variable parameter with non-physiological meaning having units (time^{-1}), not allowing a valid inter-species or pediatric scaling and relying on the unphysical assumption of infinite time of absorption [4]. Twenty years ago or so when the development of PBPK models started, the assessment of the rate of drug input was based on permeability estimates,

namely, the PBPK models abandon the use of absorption rate constant for the assessment of the drug's input rate. Our work was based on the physiologically sound FAT concept [5]; thus, the relevant Physiologically Based Finite Time Pharmacokinetic (PBFTP) models developed were found to be a powerful tool for the pharmacokinetic analysis of oral concentration, time data. The software developed is made available to the readers as supplementary electronic material (see <http://sn.pub/PtsM9h>).

In bioavailability studies, the area under the curve from zero to infinity $[AUC]_0^\infty$, which corresponds to the indefinite integral of the concentration-time function describing the time course of drug in the body, wrongly became the golden metric for the extent of drug absorption. In reality, $[AUC]_0^\infty$ is an ideal exposure metric; intuitively, the $[AUC]_0^\tau$, where τ is the FAT, is the proper metric for the extent of drug absorption. In parallel, C_{\max} is currently used as an absorption rate metric. Under the FAT concept, the concentration at time τ , $C(\tau)$ corresponds to drug concentration at the termination of the drug absorption process(es). In this vein, the numerical value of the observed maximum blood drug concentration equal to or greater than $C(\tau)$ should be used as such. This means that the magnitude of its difference between reference and test formulations in bioequivalence studies should be specified on pharmacological-pharmacodynamic basis for each one of the drugs examined. For example, critical dose drugs with narrow therapeutic index, e.g., cyclosporine, can have a smaller absolute difference and/or an upper/lower boundary for the test and reference formulations. These considerations point to the abolishment of the term "rate" in the definition of bioavailability and the use of the relevant parameter C_{\max} accompanied with statistical criteria as an indicator of the rate of absorption.

The book is divided into two parts. In Part I, the first two chapters are devoted to the mathematics associated with the unphysical hypothesis of infinite absorption time as well as the extensive use of the absorption rate constant in biopharmaceutics and pharmacokinetics since 1953. Chapter 3 focuses on the development of the FAT concept, while the relevant PBFTP models are described in Chap. 4. In Part II, Chap. 5 relies on the historical aspects of the bioavailability and bioequivalence concepts. The evolution of bioequivalence studies for the establishment of therapeutic equivalence of test and reference formulations is the subject of Chap. 6. Bioavailability is analyzed under the prism of the FAT concept in Chap. 7. Methodologies for the estimation of absolute bioavailability from oral data exclusively are reported for the first time. In Chap. 8, a methodology towards the revision of the bioequivalence assessment is presented.

This book is intended for academics/students or scientists working in pharmaceutical industries, regulatory agencies, and contract research organizations. It can be used for teaching purposes in undergraduate courses dealing with biopharmaceutics, pharmacokinetics, and biomedical engineering. However, the content of Chap. 4 and the relevant PBFTP software applications are suitable for postgraduate courses of these disciplines. In parallel, as already mentioned, the use

of the PBFTP software is made possible to the readers through the electronic supplementary material accompanying this book.

A number of obvious applications of the FAT concept for pharmacometricians to important topics have not been included in this edition. For example, all software dealing with oral drug absorption in PBPK modeling work generates percent absorbed versus time profiles which are distorted and shifted to the right. This is the net result of the integral from zero to infinity applied to solve the differential equations describing the rate of the drug input processes. In a similar vein, in vitro in vivo correlations require reconsideration since all methodologies applied, c.f., Wagner-Nelson, Loo-Riegelman, and deconvolution techniques for the %absorbed versus time curve, utilize $[AUC]_0^\infty$ and not $[AUC]_0^r$ in the numerical integration step. In oral, pulmonary and intranasal pharmacokinetic and pharmacokinetic–pharmacodynamic population studies, the structural models used so far do not include the duration of absorption, τ as a fundamental parameter of the model. This is particularly so for studies under fed conditions; the PBFTP models developed herein are the most suitable to be used in population Pharmacokinetic–Pharmacodynamic studies. Similar applications to interspecies and pediatric scaling can be also envisaged.

The book was conceived the summer of 2021 when we realized that the estimation of absolute bioavailability can be achieved from oral data exclusively.

P.M. expresses his gratitude to the current Minister of Education of Greece Mrs Niki Kerameos for implementing (Law 4957/2022) his plea to allow professors after obligatory retirement to mentor graduate students, which was included in the acknowledgement section of his recent publications [4–9].

References

1. Bonate PL ((2022)) Editor's note on the themed issue: integration of machine learning and quantitative systems pharmacology. *J. Pharmacokin. Pharmacodyn* 49:1–3 <https://doi.org/10.1007/s10928-022-09803-1>
2. Dost FH (1953) *Der Blutspiegel. Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit*. Thieme, Leipzig
3. Bateman H (1910) The solution of a system of differential equations occurring in the theory of radioactive transformations. *Proc Cambridge Philos Soc Math Phys Sci* 15:423–427. <https://www.biodiversitylibrary.org/item/97262#page/487/mode/1up> or https://archive.org/details/cbarchive_122715_solutionofasystemofdifferential1843
4. Macheras P (2019) On an unphysical hypothesis of Bateman equation and its implications for pharmacokinetics. *Pharm Res* 36:94. <https://doi.org/10.1007/s11095-019-2633-4>
5. Macheras P, Chryssafidis P (2020) Revising pharmacokinetics of oral drug absorption: I models based on biopharmaceutical/physiological and finite absorption time concepts. *Pharm Res* 37:187. <https://doi.org/10.1007/s11095-020-02894-w>

6. Macheras P, Kosmidis K, Chryssafidis P (2020) Demystifying the spreading of pandemics I: The fractal kinetics SI model quantifies the dynamics of COVID-19, meRxiv. <https://doi.org/10.1101/2020.11.15.20232132>
7. Chryssafidis P, Tsekouras AA, Macheras P (2021) Revising pharmacokinetics of oral drug absorption: II Bioavailability-bioequivalence considerations. *Pharm Res* 38:1345–1356. <https://doi.org/10.1007/s11095-021-03078-w>
8. Tsekouras AA, Macheras P (2021) Re-examining digoxin bioavailability after half a century: Time for changes in the bioavailability concepts. *Pharm Res* 38: 1635–1638. <https://doi.org/10.1007/s11095-021-03121-w>
9. Chryssafidis P, Tsekouras AA, Macheras P (2022) Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPk) models. *Pharm Res* 39:691–701. <https://doi.org/10.1007/s11095-022-03230-0>

NOTE: The Electronic Supplementary Material of this book can be accessed at <http://sn.pub/PtsM9h> or via this QR.



Athens, Greece
August 2022

Panos Macheras
Athanasios A. Tsekouras

Contents

Part I Oral Pharmacokinetics

1 From Bateman (1910) to Dost (1953)	3
1.1 Harry Bateman: First-Order Kinetics in Physics (1910)	4
1.2 Friedrich Hartmut Dost: First-Order Kinetics in Pharmacokinetics (1953)	5
1.3 Simulations Based on Bateman’s Equation	6
1.4 The Fundamental Metrics of Bioavailability/Bioequivalence Studies	7
References	8
2 The Unphysical Hypothesis of Infinite Absorption Time	9
2.1 The Biopharmaceutical–Pharmacokinetic Basis of the Bateman Equation	10
2.2 State of the Art in Oral Drug Absorption	11
2.2.1 The PK Route	12
2.2.2 The Bioph Route	14
2.2.3 The Absorption Rate Constant (k_a) Links the Bioph and PK Routes	16
2.3 The Unphysical Hypothesis of Infinite Absorption Time	17
2.4 Concluding Remarks	20
References	20
3 The Finite Absorption Time (FAT) Concept	25
3.1 Sink Conditions Imply Zero-Order Kinetics	26
3.2 Finite Absorption Time	27
3.2.1 Modeling Work: Combining BCS with Absorption Kinetics	29
3.3 Simulations	33
3.3.1 Physiological Considerations	35
3.3.2 Drug Absorption: Reconsidered in Terms of the FAT	37
3.4 Fits to Data	38

3.5	Epilogue	40
	References	41
4	The Rise of Physiologically Based Finite Time Pharmacokinetic (PBFTPk) Models	43
4.1	Models	43
4.2	Simulations	48
4.3	Fits to Data	58
4.4	Toward a Biopharmaceutics–Pharmacokinetic Classification System (BPCS)	73
4.5	Future Work	76
	References	76
Part II Bioavailability-Bioequivalence		
5	History of the Bioavailability–Bioequivalence Concepts	81
5.1	Early 1900s–Today: Variations in Response to Xenobiotics	82
5.2	1950s: The First Pharmacokinetic–Pharmacodynamic Correlations	82
5.3	1953: The Publication of Dost’s First Pharmacokinetics Book in History	83
5.4	1960s: Biopharmaceutics–Pharmacokinetics at Its Infancy	84
5.5	“The Bioavailability Problem”	84
5.6	The Introduction of an Official Dissolution Test in 1970 (USP Apparatus 1)	86
5.7	FDA (1977): Bioavailability Is the Rate and Extent to Which the Active Ingredient or Active Moiety Is Absorbed from a Drug Product and Becomes Available at the Site of Action	87
5.7.1	A Persisting Problem: The Use of C_{\max} as a Metric of Rate of Absorption	88
	References	89
6	Therapeutic Equivalence Based on Bioequivalence Studies	93
6.1	From 1977 to Now: Bioequivalence Criteria and Issues	93
6.2	Highly Variable Drugs or Drug Products (HVD)	95
6.3	Epilogue	97
	References	97
7	Bioavailability Under the Prism of Finite Absorption Time	99
7.1	The Columbus’ Egg: Drug Absorption Takes Place Under Sink Conditions for Finite Time	100
7.2	A Paradigm Shift in Oral Drug Absorption	101
7.3	Bioavailability Parameters Under the Prism of Finite Absorption Time Concept	102
7.3.1	One Compartment Model with One Constant Input Rate Operating for Time τ	102

7.3.2	One Compartment Model with More than One Constant Input Rates Operating for a Total Time τ	103
7.3.3	One Compartment Model with First-Order Absorption Lasting for Time τ and First-Order Elimination	105
7.4	Extent (Exposure) and Rate Metrics	107
7.5	Extent and Rate of Absorption Metrics Under the Prism of Finite Absorption Time (FAT)	110
7.6	Scientific-Regulatory Implications	112
7.7	Toward the Unthinkable: Estimation of Absolute Bioavailability from Oral Data Exclusively	113
	References	118
8	Bioequivalence Under the Prism of Finite Absorption Time	121
8.1	Reconsidering Digoxin Bioavailability/Bioequivalence Studies in the Light of Finite Absorption Time Concept	122
8.2	$[AUC]_0^{\tau}$ Is the Proper Metric for Drug's Extent of Absorption	124
8.3	Toward the Revision of Bioequivalence Assessment	125
8.4	Does FDA's Bioavailability Definition of 1977 Require Reconsideration?	126
	References	129